当前位置： SCI文献检索 > CONTRACEPTION期刊下所有文献 > Two-year treatment with oral contraceptives in hyperprolactinemic patients.

Two-year treatment with oral contraceptives in hyperprolactinemic patients.

Abstract：

:The aim of this prospective study was the follow-up for 2 years in symptoms, serum prolactin (PRL) levels, and radiological aspects of a group of young patients using oral contraceptives (OC) with hyperprolactinemia. A total of 16 hyperprolactinemic women (eight with idiopathic hyperprolactinemia and eight with pituitary microadenoma) who started OC use were admitted in the study. After 2 years of OC use, the assessable patients showed a nonsignificant decrease in plasma PRL level (26.8 +/- 29.4 micrograms/mL, range 4.2-97.1 micrograms/mL vs 56.3 +/- 31.5 micrograms/mL, range 23.5-144 micrograms/mL). No patient experienced any radiological changes during OC treatment. In conclusion, although the number of observations is limited, the data suggest that after 2 years of follow-up, no harmful effect of OC use was observed in these patients. :Recent case-control studies have failed to document any growth of pituitary adenomas following oral contraceptive (OC) use. The present study, involving 16 hyperprolactinemic OC users (8 with idiopathic and 8 with pituitary microadenoma) from Milan, Italy, also suggested exogenous estrogen has no harmful effects on these patients. Study participants underwent two blood collections before OC initiation for measurement of basal prolactin levels as well as a pituitary computed tomography or nuclear magnetic resonance scan. During OC use, prolactin measurements were taken between days 5-10 during cycles 6, 12, 18, and 24. At the end of the 24-month treatment period, all women underwent a second radiologic examination. After 2 years of OC use, women showed a nonsignificant decrease in plasma serum prolactin levels (median, 26.8 +or- 29.4 mcg/ml; range, 23.5-144 mcg/ml). No radiologic changes occurred. No patient experienced a prolactinoma enlargement during OC use. Despite a lack of evidence, OC administration is often considered contraindicated in hyperprolactinemic women.

journal_name

Contraception

journal_title

Contraception

authors

Testa G,Vegetti W,Motta T,Alagna F,Bianchedi D,Carlucci C,Bianchi M,Parazzini F,Crosignani PG

doi

10.1016/s0010-7824(98)00069-9

subject

Has Abstract

pub_date

1998-08-01 00:00:00

pages

69-73

issue

eissn

0010-7824

issn

1879-0518

pii

S0010-7824(98)00069-9

journal_volume

pub_type

临床试验,杂志文章

在线工具

Two-year treatment with oral contraceptives in hyperprolactinemic patients.